Cited by 421Schizophrenia research and treatmentPharmacology and Obesity TreatmentParkinson's Disease Mechanisms and Treatments

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

Open access

Koro, Carol E, Fedder, Donald O, L'Italien, Gilbert J, Weiss, SheilaS, Magder, LaurenceS, Kreyenbuhl, Julie, Revicki, DennisA, Buchanan, RobertW·2002·BMJ

DOI 10.1136/bmj.325.7358.243PMC PMC117636

Open this paper in CoChat — free account Open PDF

Abstract

Objective : To quantify the association between olanzapine and diabetes. Design : Population based nested case-control study. Setting : United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000. Participants : 19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls. Main outcome measures : Diagnosis and treatment of diabetes. Results : Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8). Conclusion : Olanzapine is associated with a clinically important and significant increased risk of diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.325.7358.243

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Logistic Regression: A Self-Learning Text.
Selvin, S., & Kleinbaum, D. G. (1996) · Journal of the American Statistical Association · doi:10.2307/2291427 · Cited by 1,628
The UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 624
Novel antipsychotics and new onset diabetes
Wirshing, D. A., Spellberg, B. J., Erhart, S. M., Marder, S. R., & Wirshing, W. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00100-0 · Cited by 407
Valproate, lamotrigine, and insulin‐mediated risks in women with epilepsy
Isojärvi, J. I. T., Rättyä, J., Myllylä, V. V., Knip, M., Koivunen, R. M., Pakarinen, A., Tekay, A., & Tapanainen, J. S. (1998) · Annals of Neurology · doi:10.1002/ana.410430406 · Cited by 342
The General Practice Research Database
Wood, L., & Martínez, C. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00004 · Cited by 330
Elevated Levels of Insulin, Leptin, and Blood Lipids in Olanzapine-Treated Patients With Schizophrenia or Related Psychoses
Melkersson, K. I., Hulting, A., & Brismar, K. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1006 · Cited by 300
THE METABOLIC EFFECTS OF EPINEPHRINE AND RELATED AMINES
Ellis, S. (1956) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06998-4 · Cited by 288
A Retrospective Comparison of Weight, Lipid, and Glucose Changes Between Risperidone- and Olanzapine-Treated Inpatients
Meyer, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0509 · Cited by 267

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 2

Caro, 2000, Atypical antipsychotics and the risk of developing diabetes. International Society for Pharmacoeconomics and Outcomes Research European meeting, Belgium, 2000., Value Health, 3, MH2
10.1176/appi.ajp.124.7.978 · DOI

Sorted by citations

Items 101–200 of 420

Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs
Taylor, D. M., Young, C., Mohamed, R., Paton, C., & Walwyn, R. E. A. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105049039 · Cited by 59
Risk of Diabetes Mellitus Associated with Atypical Antipsychotic Use Among Medicaid Patients with Bipolar Disorder: A Nested Case‐Control Study
Guo, J. J., Keck, P. E., Corey‐Lisle, P. K., Li, H., Jiang, D., Jang, R., & L'Italien, G. J. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.1.27 · Cited by 57
Self-citation
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
American Psychiatric Association American Diabetes Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Obesity Research · doi:10.1038/oby.2004.46 · Cited by 57
Atypical antipsychotics and hyperglycemic emergencies: Multicentre, retrospective cohort study of administrative data
Lipscombe, L. L., Austin, P. C., Alessi‐Severini, S., Blackburn, D. F., Blais, L., Bresee, L. C., Filion, K. B., Kawasumi, Y., Kurdyak, P. A., Platt, R. W., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.01.043 · Cited by 56
Multi‐country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study
Pratt, N. L., Andersen, M. T., Bergman, U., Choi, N., Gerhard, T., Huang, C. S., Kimura, M., Kimura, T., Kubota, K., Lai, E. C., et al. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3440 · Cited by 55
The metabolic syndrome and schizophrenia: A review
Meyer, J. M., Koro, C. E., & L'Italien, G. J. (2005) · International Review of Psychiatry · doi:10.1080/09540260500071798 · Cited by 55
Self-citation
New-onset type-2 diabetes associated with atypical antipsychotic medications
Lambert, M. T., Copeland, L. A., Sampson, N., & Duffy, S. A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.02.007 · Cited by 55
How can research ethics committees protect patients better?
Garattini, S. K., Bertele, V., & Bassi, L. L. (2003) · BMJ · doi:10.1136/bmj.326.7400.1199 · Cited by 54
A review of atypical antipsychotic drugs versus conventional medication in schizophrenia
Luft, B., & Taylor, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.13.1739 · Cited by 52
Glucose and lipid metabolism of long‐term risperidone monotherapy in patients with schizophrenia
Murashita, M. M., Inoue, T., Kusumi, I., Nakagawa, S., Itoh, K., Tanaka, T., Izumi, T., Hosoda, H., Kangawa, K., & Koyama, T. (2007) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2007.01610.x · Cited by 51
Diabetes mellitus and antipsychotic treatment in the United Kingdom
Carlson, C. D., Hornbuckle, K., Delisle, F., Kryzhanovskaya, L. A., Breier, A. F., & Cavazzoni, P. A. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.11.002 · Cited by 49
Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment
Cohen, D., Dekker, J., Peen, J., & Wied, C. C. G. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.09.003 · Cited by 49
Exploring the Association Between Atypical Neuroleptic Agents and Diabetes Mellitus in Older Adults
Etminan, M., Streiner, D. L., & Rochon, P. A. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.14.1411.31939 · Cited by 49
Mifepristone Reduces Weight Gain and Improves Metabolic Abnormalities Associated With Risperidone Treatment in Normal Men
Gross, C., Blasey, C. M., Roe, R. L., & Belanoff, J. K. (2010) · Obesity · doi:10.1038/oby.2010.51 · Cited by 47
Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Ollendorf, D. A., Joyce, A. T., & Rucker, M. (2004) · PubMed · Cited by 47
Squamous cell carcinomas of the head and neck
Joshi, V. K. (2003) · BMJ · doi:10.1136/bmj.326.7383.282 · Cited by 46
Changes in coronary heart disease risk profile of adults with intellectual disabilities following a physical activity intervention
Moss, S. J. (2009) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2009.01187.x · Cited by 46
Naturalistic Impact of Second-Generation Antipsychotics on Weight Gain
Brixner, D. I., Said, Q., Corey‐Lisle, P. K., Tuomari, A. V., L'Italien, G. J., Stockdale, W., & Oderda, G. M. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g564 · Cited by 46
Self-citation
Why and how antipsychotic drugs are used in 40 Sydney nursing homes
Snowdon, J. A., Day, S., & Baker, W. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1407 · Cited by 46
Antipsychotic drug treatment for elderly people with late-onset schizophrenia
Essali, A., & Ali, G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004162.pub2 · Cited by 45
Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
Yogaratnam, J., Biswas, N., Vadivel, R., & Jacob, R. (2013) · PubMed · Cited by 42
Benzo- and Thienobenzo- Diazepines: Multi-target Drugs for CNS Disorders
Junior, F. J. B., Scotti, L., Ishiki, H. M., Botelho, S. P. S., da Silva, M. S., & Scotti, M. T. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150219125030 · Cited by 44
Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects.
Conley, R. R., & Kelly, D. L. (2005) · PubMed · Cited by 44
Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy
Cui, D., Peng, Y., Zhang, C., Li, Z., Su, Y., Qi, Y., Xing, M., Li, J., Kim, G. E., Su, K. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93090 · Cited by 44
Intramuscular Olanzapine
Wagstaff, A. J., Easton, J., & Scott, L. J. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00005 · Cited by 43
Risk of Diabetic Ketoacidosis after Exposure to Risperidone or Olanzapine
Ramaswamy, K., Kozma, C. M., & Nasrallah, H. A. (2007) · Drug Safety · doi:10.2165/00002018-200730070-00004 · Cited by 43
Olanzapine alone or in combination for acute mania
Rendell, J. M., Gijsman, H. J., Keck, P. K., Goodwin, G. M., & Geddes, J. R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004040 · Cited by 43
Endotoxaemia resulting from decreased serotonin tranporter (5-HTT) function: A reciprocal risk factor for depression and insulin resistance?
Анатольевич, П. И., Cline, B. H., Anthony, D. C., Steinbusch, H. W. M., Lesch, K., & Strekalova, T. V. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.04.049 · Cited by 45
The Metabolic Syndrome During Atypical Antipsychotic Drug Treatment: Mechanisms and Management
Baptista, T., Mendoza, S., Beaulieu, S., Bermúdez, A., & Martinez, M. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.290 · Cited by 42
A Walking Program for Outpatients in Psychiatric Rehabilitation: Pilot Study
McDevitt, J. H., Wilbur, J., Kogan, J. A., & Briller, J. E. (2005) · Biological Research For Nursing · doi:10.1177/1099800405278116 · Cited by 42
Retrospective Cohort Study of Diabetes Mellitus and Antipsychotic Treatment in a Geriatric Population in the United States
Feldman, P. D., Hay, L. K., Deberdt, W. G., Kennedy, J. S., Hutchins, D. S., Hay, D. P., Hardy, T. A., Hoffmann, V. P., Hornbuckle, K., & Breier, A. F. (2004) · Journal of the American Medical Directors Association · doi:10.1016/s1525-8610(04)70042-0 · Cited by 42
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone
Lee, S., Park, M.-H., Patkar, A. A., & Pae, C. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.003 · Cited by 40
Exposure to Potentially Dangerous Drug-Drug Interactions Involving Antipsychotics
Guo, J. J., Wu, J., Kelton, C. M. L., Jing, Y., Fan, H., Keck, P. E., & Patel, N. C. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201100443 · Cited by 40
Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients
de Almeida, V., Alexandrino, G. L., Aquino, A., Gomes, A. F., Murgu, M., Dobrowolny, H., Guest, P. C., Steiner, J., & Martins-de-Souza, D. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109945 · Cited by 39
Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era
Basu, A., & Meltzer, H. Y. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.04.014 · Cited by 39
Pharmaco-epidemiology: What do (and don't) we know about utilisation and impact of psychotropic medications in real-life conditions?
Verdoux, H., & Bégaud, B. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.185.2.93 · Cited by 39
Clinical Rating Scales and Instruments
Dean, C. E., Russell, J. M., Kuskowski, M. A., Caligiuri, M. P., & Nugent, S. M. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000125681.97466.e7 · Cited by 38
A Retrospective Chart Review of the Antiemetic Effectiveness of Risperidone in Refractory Opioid-Induced Nausea and Vomiting in Advanced Cancer Patients
Okamoto, Y., Tsuneto, S., Matsuda, Y., Inoue, T., Tanimukai, H., Tazumi, K., Ono, Y., Kurokawa, N., & Uejima, E. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.10.020 · Cited by 37
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression
Vanelle, J., & Douki, S. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2006.09.003 · Cited by 35
Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure
Sacchetti, E., Turrina, C., Parrinello, G., Brignoli, O., Stefanini, G., & Mazzaglia, G. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200501000-00007 · Cited by 36
Five-year mortality of Finnish schizophrenia patients in the era of deinstitutionalization
Rantanen, H., Koivisto, A., Salokangas, R. K. R., Helminen, M., Oja, H., Pirkola, S. P., Wahlbeck, K., & Joukamaa, M. I. (2008) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-008-0414-1 · Cited by 39
Fatal Olanzapine-Induced Hyperglycemic Ketoacidosis
Avella, J., Wetli, C. V., Wilson, J. C., Katz, M., & Hahn, T. (2004) · American Journal of Forensic Medicine & Pathology · doi:10.1097/01.paf.0000127391.85007.f4 · Cited by 35
Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study
Østbye, T., Curtis, L. H., Masselink, L. E., Hutchison, S., Wright, A., Dans, P. E., Schulman, K. A., & Krishnan, R. R. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1016 · Cited by 35
C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice
Sicras‐Mainar, A., Rejas, J., Navarro‐Artieda, R., & Blanca-Tamayo, M. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.07.003 · Cited by 35
Weight gain and metabolic issues of medicines used for bipolar disorder
Fagiolini, A. M., & Chengappa, K. N. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0071-1 · Cited by 33
Metabolic and Endocrine Disturbances in Psychiatric Disorders: A Multidisciplinary Approach to Appropriate Atypical Antipsychotic Utilization
Masand, P. S., Culpepper, L., Henderson, D. C., Lee, S., Littrell, K. H., Newcomer, J. W., & Rasgon, N. (2005) · CNS Spectrums · doi:10.1017/s1092852900025499 · Cited by 33
Clinical Experience with Aripiprazole Treatment in Ten Elderly Patients with Schizophrenia or Schizoaffective Disorder: Retrospective Case Studies
Madhusoodanan, S., Brenner, R., Gupta, S., Reddy, H., & Bogunovic, O. J. (2004) · CNS Spectrums · doi:10.1017/s1092852900002273 · Cited by 33
Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management
Chue, P., & Kovacs, C. S. (2003) · Bipolar Disorders · doi:10.1111/j.1399-2406.2003.00063.x · Cited by 32
Atypical antipsychotics and diabetes mellitus
Schwenkreis, P., & Assion, H. (2004) · The World Journal of Biological Psychiatry · doi:10.1080/15622970410029915 · Cited by 32
Genetic Correlates of Olanzapine-Induced Weight Gain in Schizophrenia Subjects from North India: Role of Metabolic Pathway Genes
Srivastava, V., Deshpande, S. N., Nimgaonkar, V. L., Lerer, B., & Thelma, B. K. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.8.1055 · Cited by 31
Incidence and Costs of Cardiometabolic Conditions in Patients with Schizophrenia Treated with Antipsychotic Medications
Jerrell, J., McIntyre, R., & Tripathi, A. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.3.2 · Cited by 31
Challenges and Opportunities for Pharmacoepidemiology in Drug‐Therapy Decision Making
Etminan, M., Gill, S. S., Fitzgerald, M., & Samii, A. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005283285 · Cited by 32
Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre
Tarricone, I., Casoria, M., Gozzi, B. F., Grieco, D., Menchetti, M., Serretti, A., Ujkaj, M., Pastorelli, F., & Berardi, D. (2006) · BMC Psychiatry · doi:10.1186/1471-244x-6-11 · Cited by 31
Incidence of Diabetes in Patients with Schizophrenia: A Population-Based Study
Hsu, J., Chien, I., Lin, C., Chou, Y., & Chou, P. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600105 · Cited by 31
Correlates of response to Olanzapine in a North Indian Schizophrenia sample
Thomas, P., Srivastava, V., Singh, A., Mathur, P., Nimgaonkar, V. L., Lerer, B., Thelma, B. K., & Deshpande, S. N. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.09.010 · Cited by 31
Antipsychotic prescribing in older people
Neil, W., Curran, S., & Wattis, J. P. (2003) · Age and Ageing · doi:10.1093/ageing/afg061 · Cited by 31
Drug-induced endocrine disorders in the intensive care unit
Thomas, Z., Bandali, F., McCowen, K., & Malhotra, A. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181dda0f2 · Cited by 30
Association between anxiety and metabolic syndrome: An updated systematic review and meta-analysis
Ji, S., Chen, Y., Zhou, Y., Cao, Y., Li, X., Ding, G., & Tang, F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1118836 · Cited by 35
Troubles métaboliques associés aux antipsychotiques atypiques : consensus belge sur la conduite à tenir
DeNayer, A., DeHert, M., Scheen, A. J., VanGaal, L., & Peuskens, J. (2007) · L Encéphale · doi:10.1016/s0013-7006(07)91550-x · Cited by 30
Comparison of the metabolic and economic consequences of long‐term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost‐effectiveness analysis
McIntyre, R. S., Cragin, L. S., Sorensen, S. V., Naci, H., Baker, T., & Roussy, J. (2010) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2009.01189.x · Cited by 30
Are females at special risk of obesity if they become psychotic? The longitudinal Northern Finland 1966 Birth Cohort Study
Hakko, H. H., Komulainen, M. T., Koponen, H., Saari, K., Laitinen, J. H., Järvelin, M., & Lindeman, S. M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.020 · Cited by 29
Topical Corticosteroids and the Risk of Diabetes Mellitus
van der Linden, M. W., Beest, F. J. A. P., Nijsten, T. E. C., & Herings, R. M. C. (2009) · Drug Safety · doi:10.2165/00002018-200932060-00008 · Cited by 29
Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone
Larmo, I., de Nayer, A., Windhager, E., Irmansyah, Lindenbauer, B., Rittmannsberger, H., Platz, T., Jones, A., & Altman, C. A. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.723 · Cited by 29
Ambulatory Use of Olanzapine and Risperidone: A Population-Based Study on Persistence and the Use of Concomitant Therapy in the Treatment of Schizophrenia
Cooper, D., Moisan, J., Gaudet, M., Abdous, B., & Grégoire, J. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505001404 · Cited by 29
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
Yagoda, S., Graham, C. E., Simmons, A., Arevalo, C., Jiang, Y., & McDonnell, D. (2020) · CNS Spectrums · doi:10.1017/s1092852920001376 · Cited by 28
Metabolic Risk with Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-Week Trial of Risperidone and Olanzapine
Kelly, D. L., Conley, R. R., Love, R. C., Morrison, J. A., & McMahon, R. P. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230802017050 · Cited by 28
Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine‐induced weight gain
Belanoff, J. K., Blasey, C. M., Clark, R. D., & Roe, R. L. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01185.x · Cited by 27
Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model
Vera‐Llonch, M., Delea, T. E., Richardson, E., Rupnow, M. F. T., Grogg, A. L., & Oster, G. (2004) · Value in Health · doi:10.1111/j.1524-4733.2004.75008.x · Cited by 27
The metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?
Meltzer, H. Y. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005183 · Cited by 27
Antipsychotics and the risk of diabetes: A general data review
Bottaï, T., Quintin, P., & Perrin, E. (2005) · European Psychiatry · doi:10.1016/s0924-9338(05)80190-7 · Cited by 27
Psychological Issues in Adults with Type 2 Diabetes
Gonzalez, J. S., Esbitt, S. A., Schneider, H. E., Osborne, P. J., & Kupperman, E. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0029-6_2 · Cited by 30
Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications
Cavazzoni, P. A., Mukhopadhyay, N. D., Carlson, C. D., Breier, A. F., & Buse, J. B. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.184.47.s94 · Cited by 26
Frequency of New‐Onset Diabetes Mellitus and Use of Antipsychotic Drugs Among Central Texas Veterans
Barner, J. C., Worchel, J., & Yang, M. S. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.16.1529.50952 · Cited by 26
A Comparison of Incidence of Diabetes Mellitus Between Atypical Antipsychotic Drugs: A Survey for Clozapine, Risperidone, Olanzapine, and Quetiapine
Sumiyoshi, T., Roy, A., Anil, A. E., Jayathilake, K., Ertugrul, A., & Meltzer, H. Y. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000126668.67820.00 · Cited by 28
The overweight: obesity and plasma lipids in adults with intellectual disability and mental illness
Gazizova, D., Puri, B. K., Singh, I., & Dhaliwal, R. (2011) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2011.01468.x · Cited by 25
Risk factors for coronary heart disease among inpatients who have mild intellectual disability and mental illness
Merriman, S., Haw, C., Kirk, J., & Stubbs, J. H. (2005) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2005.00600.x · Cited by 25
Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population‐based comparison of risperidone and olanzapine
Moisan, J., Grégoire, J., Gaudet, M., & Cooper, D. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1093 · Cited by 25
Retrospective Analysis of Diabetes Risk in Elderly Patients With Dementia in Olanzapine Clinical Trials
Micca, J. L., Hoffmann, V. P., Lipkovich, I. A., AHL, J. S. B., Baker, R. W., & Hardy, T. A. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000192477.05061.96 · Cited by 24
The cost-effectiveness of atypicals in the UK.
Heeg, B., Buskens, E., Botteman, M., Caleo, S., Ingham, M., Damen, J., de Charro, F. D., & van Hout, B. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00344.x · Cited by 25
Evidence that lithium protects against tardive dyskinesia: The Curaçao Extrapyramidal Syndromes study VI
van Harten, P. N., Hoek, H. W., Matroos, G. E., & van Os, J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.07.004 · Cited by 24
Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design
Gianfrancesco, F. D., Pesa, J. A., Wang, R., & Nasrallah, H. A. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050144 · Cited by 24
Association Between Antipsychotic Treatment and Hyperlipidemia Among California Medicaid Patients With Schizophrenia
Lambert, B. L., Chang, K.-Y., Tafesse, E., & Carson, W. H. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150224.38630.ae · Cited by 24
Diabetes Mellitus Associated with Atypical Anti-Psychotic Medications
Clark, C., & Burge, M. R. (2003) · Diabetes Technology & Therapeutics · doi:10.1089/152091503322250695 · Cited by 24
WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics
Grauer, S. M., Graf, R., Navarra, R. L., Sung, A., Logue, S. F., Stack, G., Huselton, C. A., Liu, Z., Comery, T. A., Marquis, K. L., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1433-z · Cited by 23
Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., & Möller, H. (2006) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832006000700003 · Cited by 24
Diabetic retinopathy screening in persons with mental illness: a literature review
Bradley, E. R., & Delaffon, V. (2020) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2020-000437 · Cited by 22
Psychiatric disorder in early adulthood and risk of premature mortality in the 1946 British Birth Cohort
Henderson, M., Hotopf, M. H., Shah, I., Hayes, R. D., & Kuh, D. J. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-37 · Cited by 22
Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects
Chong, J. W. X., Tan, E. H.-J., Chong, C. E., Ng, Y., & Wijesinghe, R. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.07.178 · Cited by 22
Diabetes Prevalence Estimates in Schizophrenia and Risk Factor Assessment
Argo, T. R., Carnahan, R. M., Barnett, M. J., Holman, T. L., & Perry, P. J. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300206 · Cited by 22
Clinical Trial Response and Dropout Rates with Olanzapine versus Risperidone
Santarlasci, B., & Messori, A. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c291 · Cited by 22
Controversies in the use of second generation antipsychotics as sleep agent
Shah, C., Sharma, T. R., & Kablinger, A. S. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.10.005 · Cited by 21
Antipsychotics and risk of first‐time hospitalization for myocardial infarction: a population‐based case–control study
NAKAGAWA, S., Pedersen, L. H., OLSEN, M. L., Mortensen, P. B., Sørensen, H. T., & Johnsen, S. P. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01708.x · Cited by 21
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
Citrome, L., Graham, C. E., Simmons, A., Jiang, Y., Todtenkopf, M. S., Silverman, B. L., DiPetrillo, L., Cummings, H., Sun, L., & McDonnell, D. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s313840 · Cited by 21
Risperidone in acute and long-term therapy of schizophrenia—a clinical profile
Pajonk, F. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00164-7 · Cited by 21
Cost Effectiveness of Long-Acting Risperidone in Sweden
Hensen, M., Heeg, B. M. S., Löthgren, M., & van Hout, B. (2010) · Applied Health Economics and Health Policy · doi:10.2165/11536180-000000000-00000 · Cited by 20
Impact of Medical Comorbidity on the Quality of Schizophrenia Pharmacotherapy in a National VA Sample
Chwastiak, L., Rosenheck, R. A., & LESLIE, D. L. (2005) · Medical Care · doi:10.1097/01.mlr.0000188993.25131.48 · Cited by 20
Antipsychotic Use and the Risk of Diabetes in Nursing Home Residents with Dementia
Jalbert, J. J., Daiello, L. A., Eaton, C. B., Miller, S. C., & Lapane, K. L. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.04.006 · Cited by 20
Life-Threatening Hyperglycemia and Acidosis Related to Olanzapine: A Case Report and Review of the Literature
Varma, M. K., Connolly, K., & Fulton, B. (2007) · Journal of Intensive Care Medicine · doi:10.1177/0885066606295823 · Cited by 20
Use of psychopharmacologic agents in the elderly
Desai, A. K. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(03)00044-2 · Cited by 20
Generating Evidence to Inform Policy and Practice: The Example of the Second Generation "Atypical" Antipsychotics
Geddes, J. R. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006980 · Cited by 20

Authors: Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R.
Affiliations: University of Maryland, Baltimore (US)
Corresponding author: Koro, Carol E
ORCID: Kreyenbuhl, Julie
Venue: BMJ
Publisher: BMJ
Published: 2002-08-03
Volume: 325
Issue: 7358
Pages: 243
ISSN: 0007-1447 (ISSN-L)
0959-8138
1468-5833
DOI: 10.1136/bmj.325.7358.243
PMC: PMC117636
OpenAlex: W2160802754
Cited by: 421
References: 30
Citations by year: 2026: 3 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 3 · 2018: 7 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 5 · 2013: 10 · 2012: 9
FWCI: 37.10
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
Locations: BMJ (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords: olanzapine, risperidone, schizophrenia, diabetes risk, antipsychotic drugs, adverse drug reactions, typical antipsychotics, type 2 diabetes
MeSH terms: Olanzapine, Adult, Aged, Benzodiazepines, Diabetes Mellitus, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pirenzepine, Regression Analysis, Risk Factors, Schizophrenia, Antipsychotic Agents, Cohort Studies, Odds Ratio, Case-Control Studies, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks